AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Bill Tracker · Nebraska

LB877

Designate certain substances as controlled substances under the Uniform Controlled Substances Act

Status

Enacted

109th Legislature, Second Session (2026)

Not a reform bill: LB877 adds substances to Nebraska's controlled-substances schedules. It tightens drug restrictions; it does not legalize, decriminalize or expand psychedelic access.

IntroducedJan 8, 2026 (done)
PassedFeb 27, 2026 (done)
SignedMar 3, 2026 (done)
Law in effectNext step (current)

Session dates: January 7, 2026 – April 17, 2026

Official text

The full bill text and every version are kept by the legislature. We link to it rather than copy it so readers always see the current version.

Read the full bill text

Source: nebraskalegislature.gov

Legislative history

No dated actions recorded yet. The progress steps above show what is confirmed.

Loading bill…